Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule.

@article{Sachs2018InnovativeCF,
  title={Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule.},
  author={Rachel Sachs and Nicholas Bagley and Darius N. Lakdawalla},
  journal={Journal of health politics, policy and law},
  year={2018},
  volume={43 1},
  pages={
          5-18
        }
}
In recent years, drug manufacturers and private payers have expressed interest in novel pricing models that more closely link a drug's price to its value. Indication-based pricing, outcome-based pricing, drug licenses, and drug mortgages have all been discussed as alternatives to paying strictly for volume. Manufacturers and payers have complained, however, that Medicaid's "best-price rule" inhibits their ability to enter into these new pricing arrangements. This article examines the best-price… 

Tables from this paper

The economics of alternative payment models for pharmaceuticals

It is shown that while uniform pricing rules can handle variable effectiveness in efficient markets, market inefficiencies of other kinds create a role for different value-based pricing structures.

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

Two classes of cancer therapy - tyrosine-kinase inhibitors (TKIs) and PD-1/PD-L1 inhibitors are identified and how competing products and competing indications have developed over time are illustrated.

Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.

  • A. Kaltenboeck
  • Medicine, Political Science
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2020

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

An overview of the key literature that has contributed to this debate, and of how IBP has been implemented – in its various forms – to date in the U.S., France, Germany, Italy, Spain and the UK, is provided.

Drug Reimbursement Regulation in 6 Peer Countries.

In this Special Communication, the drug price mechanisms and government regulations used in 6 representative peer countries are evaluated: Australia, France, Germany, Norway, Switzerland, and the United Kingdom.

Regulating Intermediate Technologies

Over the last several years, scholars studying health innovation policy have carefully considered the ways in which policymakers regulate different types of technologies to encourage their

Price Models for Multi-indication Drugs: A Systematic Review

There are no applications of pure IBP systems and their practical consequences are therefore unknown, and the system that most closely approximates an IBP model consists of agreements that are generally confidential and linked to risk-sharing agreements.

The Indirect Consequences of Expanded Off-Label Promotion

The U.S. Food and Drug Administration’s (FDA) policies have been a battleground for litigation about First Amendment protections for commercial speech. In the last five years, the FDA’s position that

References

SHOWING 1-8 OF 8 REFERENCES

Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.

Risk-sharing agreements, under which payers and pharmaceutical manufacturers agree to link payment for drugs to health outcomes achieved, rather than the volume of products used, offer an appealing

The problem of new uses.

  • R. Eisenberg
  • Business, Medicine
    Yale journal of health policy, law, and ethics
  • 2005

Harvard Pilgrim Scores Discounts on Novartis, Lilly Drugs.

  • Modern Healthcare,
  • 2016

Promoting Value-Based Contracting Arrangements.

  • January 29
  • 2016

A Fair Plan for Fairer Drug Prices.

  • Health Affairs (blog), July
  • 2016

US Outcomes-Based Contracts: Big Uptick in Interest, But Not Execution.

  • 2016